Top Markets
Coin of the day
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
株式のランク #26781
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
株価
$0.52468396
時価総額
$37.85M
変化(1日)
1.23%
変化(1年)
-4.53%
TW
取引 Enimmune corporation (6564)

カテゴリー

Enimmune corporation(6564)の配当利回りの履歴
Enimmune corporation(銘柄コード: 6564)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Enimmune corporation(6564)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)